Literature DB >> 6318663

Orally administered ketoconazole: route of delivery to the human stratum corneum.

R Harris, H E Jones, W M Artis.   

Abstract

Delivery of ketoconazole to human stratum corneum was studied. Thirteen healthy volunteers, three patients with chronic fungal disease and one patient with palmar-plantar hyperhidrosis were given 400 mg of ketoconazole daily for various lengths of time. The ketoconazole content of palmar stratum corneum, eccrine sweat, sebum, and serum was measured by high-pressure liquid chromatography (sensitivity, 0.005 to 0.010 microgram/ml). Palmar stratum corneum obtained after 7 and 14 days of daily administration contained up to 14 micrograms of ketoconazole per g. Ketoconazole was not found in sebum after 7 or 14 days of daily ingestion of the antimycotic agent. Sebum from three patients with chronic fungal infection treated for greater than 9 months contained ketoconazole (means, 4.7 micrograms/g). Thermogenic whole body eccrine sweat contained a mean of 0.059 microgram/ml on day 7 and 0.084 microgram/ml on day 14 of daily administration. Ketoconazole appeared in thermogenic whole body eccrine sweat and palmar hyperhidrotic sweat within 1 h after a single oral dose. Partition studies of ketoconazole containing eccrine sweat demonstrated a 10-fold greater concentration in the sediment phase (desquamated keratinocytes) compared with the clear supernatant phase. In vitro studies with [3H]ketoconazole-supplemented supernatant sweat revealed preferential binding to stratum corneum, hair, and nails and its partitioning to lipid-rich sebum. We conclude that eccrine sweat rapidly transports ketoconazole across the blood-skin barrier, where it may bind or partition to keratinocytes and surface lipids.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6318663      PMCID: PMC185400          DOI: 10.1128/AAC.24.6.876

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Role of sweat in accumulation of orally administered griseofulvin in skin.

Authors:  V P Shah; W L Epstein; S Riegelman
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

2.  Cell kinetics of human sebaceous glands.

Authors:  G D Weinstein
Journal:  J Invest Dermatol       Date:  1974-03       Impact factor: 8.551

3.  Griseofulvin levels in stratum corneum. Study after oral administration in man.

Authors:  W L Epstein; V P Shah; S Riegelman
Journal:  Arch Dermatol       Date:  1972-09

4.  Chemical composition of human skin surface lipids from birth to puberty.

Authors:  P Ramasastry; D T Downing; P E Pochi; J S Strauss
Journal:  J Invest Dermatol       Date:  1970-02       Impact factor: 8.551

5.  The mammalian cutaneous permeability barrier: defective barrier function is essential fatty acid deficiency correlates with abnormal intercellular lipid deposition.

Authors:  P M Elias; B E Brown
Journal:  Lab Invest       Date:  1978-12       Impact factor: 5.662

Review 6.  Permeability of the skin.

Authors:  R J Scheuplein; I H Blank
Journal:  Physiol Rev       Date:  1971-10       Impact factor: 37.312

7.  Treatment of chronic mucocutaneous candidiasis with ketoconazole: a controlled clinical trial.

Authors:  E A Petersen; D W Alling; C H Kirkpatrick
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

8.  Ketoconazole in griseofulvin-resistant dermatophytosis.

Authors:  M H Robertson; P Rich; F Parker; J M Hanifin
Journal:  J Am Acad Dermatol       Date:  1982-02       Impact factor: 11.527

9.  Determination of the antifungal agent, ketoconazole, in human plasma by high-performance liquid chromatography.

Authors:  K B Alton
Journal:  J Chromatogr       Date:  1980-12-12

10.  Oral ketoconazole. An effective and safe treatment for dermatophytosis.

Authors:  H E Jones; J G Simpson; W M Artis
Journal:  Arch Dermatol       Date:  1981-03
View more
  9 in total

Review 1.  Working Up a Good Sweat - The Challenges of Standardising Sweat Collection for Metabolomics Analysis.

Authors:  Joy N Hussain; Nitin Mantri; Marc M Cohen
Journal:  Clin Biochem Rev       Date:  2017-02

2.  Antifungal activity of ketoconazole and other azoles against Malassezia furfur in vitro and in vivo.

Authors:  V Strippoli; A Piacentini; F D D'Auria; N Simonetti
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 3.553

Review 3.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

5.  Oral ibuprofen differentially affects plasma and sweat lipid mediator profiles in healthy adult males.

Authors:  Karan Agrawal; Rémy Bosviel; Brian D Piccolo; John W Newman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-05-17       Impact factor: 3.072

Review 6.  Pharmacokinetic optimisation of oral antifungal therapy.

Authors:  M Schäfer-Korting
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

7.  Thermodynamic, Computational Solubility Parameters in Organic Solvents and In Silico GastroPlus Based Prediction of Ketoconazole.

Authors:  Sultan Alshehri; Afzal Hussain; Mohd Neyaz Ahsan; Raisuddin Ali; Mohd Usman Mohd Siddique
Journal:  ACS Omega       Date:  2021-02-11

8.  Generalized exfoliative skin rash as an early predictor of supratherapeutic voriconazole trough levels in a leukemic child: A case report.

Authors:  Ali Amanati; Parisa Badiee; Mehrzad Lotfi; Ahmad Monabati; Mohammad Ali Faghihi; Majid Yavarian; Nazafarin Hatami Mazinani
Journal:  Curr Med Mycol       Date:  2020-09

9.  Physicochemical properties determining drug detection in skin.

Authors:  Wout Bittremieux; Rohit S Advani; Alan K Jarmusch; Shaden Aguirre; Aileen Lu; Pieter C Dorrestein; Shirley M Tsunoda
Journal:  Clin Transl Sci       Date:  2021-11-28       Impact factor: 4.689

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.